Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Yu, Donghui T ^a,b,e   Seger, Diane L ^b   Peterson, Josh F ^c   Kumar, Ritesh N ^d   Bates, David W ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PARTNERS HEALTHCARE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CYCLOSPORIN; FLUCONAZOLE; PYRROLE DERIVATIVE; STEROID;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER PATIENT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LENGTH OF STAY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; OPTIMAL DRUG DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADULT; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COHORT STUDIES; FEMALE; FEVER; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MYCOSES; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

EID: 33845748649     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-173     Document Type: Article

References (39)

1. Ascioglu S, Rex JH, De Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, et al.: Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus. Clin Infect Dis 2002, 34:7.
2. Anaissie EJ, Rex JH, Uzun O, Vartivarian S: Predictors of Adverse Outcome in Cancer Patients with Candidemia. Am J Med 1998, 104:238-245.
3. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current Trends in the Epidemiology of Nosocomial Bloodstream Infections in Patients with Hematological Malignancies and Solid Neoplasms in Hospitals in the United States. Clin Infect Dis 2003, 36:1103.
4. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982, 72:101-11.
5. EORTC International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989, 86:668-72.
6. Sugar AM: Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use. Arch Intern Med 1990, 150:2258-64.
7. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, et al.: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-51.
8. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-34.
9. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, et al.: Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia. N Engl J Med 2004, 351:1391-1402.
10. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, Fanci R, Menichetti F, Caselli D, Giacchino M, et al.: Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996, 32A:814-20.
11. Malik IA, Moid I, Aziz Z, Khan S, Suleman M: A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998, 105:478-83.
12. Silling G, Fegeler W, Roos N, Essink M, Buchner T: Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses 1999, 42(Suppl 2):101-4.
13. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000, 108:282-9.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal populations: development and validation. J Chronic Dis 1987, 40:373-383.
15. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R: Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995, 274:29-34.
16. Efron B, Tibshirani RJ: An introduction to the Bootstrap. New York: Chapman and Hall; 1993.
17. Kleinbaum DG, Kupper LL, Muller KE: Applied Regression Analysis and Other Multivariable Methods. Boston, Mass: PWS-Kent; 1988.
18. SAS Procedures Guide, Release 6.12 Edition. Cary, NC: SAS Institute Inc; 1996.
19. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, Williams T, Kontoyiannis DP, Karl CL, Bodey GP: Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996, 23:964-72.
20. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, Goldman M, van Burik JA, McCabe A, Lin JS, et al.: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998, 27:296-302.
21. Bennett JE, Powers J, Walsh T, Viscoli C, De Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, et al.: Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003, 36(Suppl 3):S117-22.
22. Nucci M, Silveira MI, Spector N, Silveira F, Velasco E, Akiti T, Barreiros G, Derossi A, Colombo AL, Pulcheri W: Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998, 27:107-11.
23. Uzun O, Ascioglu S, Anaissie EJ, Rex JH: Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001, 32:1713-7.
24. Zaoutis TE, Argon J, Jaclyn C, Berlin JA, Walsh TJ, Feudtner C: The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis. Clin Infect Dis 2005, 41:1232-1239.
25. Rentz AM, Halpern MT, Bowden R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998, 27:781-8.
26. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988, 148:2642-5.
27. Menzin J, Lang KM, Friedman M, Dixon D, Marton JP, Wilson J: Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data. Value Health 2005, 8:140-8.
28. Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth WC: Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis 2004, 8:111-20.
29. Olaechea PM, Palomar M, Leon-Gil C, Alvarez-Lerma F, Jorda R, Nolla-Salas J, Leon-Regidor MA, EPCAN Study Group: Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004, 23:323-30.
30. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J: The direct cost and incidence of systemic fungal infections. Value Health 2002, 5:26-34.
31. Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CA, Schuster M, Seibel N, Yeldandi V, et al.: Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000, 18:2476-83.
32. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98:711-8.
33. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, Amph L: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000, 31:1155-63.
34. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340:764-71.
35. Marie JP, Lapierre V, Pico J, Vekhoff A, Molina L, Andremont Aea: Etude multicentrique randomisee fluconazole iv versus amphotericine B iv chez le patient neutropenique et febrile. Cahiers Oncologie 1993, 2:171-173.
36. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K, et al.: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001, 135:412-22.
37. Klastersky J: Empirical antifungal therapy. Int J Antimicrob Agents 2004, 23:105-12.
38. Wingard JR: Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004, 39(Suppl 1):S38-43.
39. Bodey G, Kontoyiannis D, Lewis R: Empiric Antifungal Therapy for Persistently Febrile Neutropenic Patients. Curr Treat Options Infect Dis 2002, 4:521-532.